“2. That one persons shortcomings may slow down its progress, but not stop it. NP will ultimately be removed if he continues to be an impediment. Too much at stake not to.”

IMO, NP has already reached the point of being too much of an impediment. I’ve suspected for some time that he overestimates that’s value of leronlimab and underestimates FDA timelines, which leads to him believing that potential BO offers, licensing deals, or financing opportunities are not good enough for leronlimab.

I’ve brought this up before and I will again: NP made a comment early in the COVID19 indication that someone approached him about a trial combining Remdesevir with leronlimab. This was long before Remdesevir was approved. He said he turned it down because leronlimab would do it on its own. Now, that still may be true, but remdesevir was approved many months ago and their trial of 800 or so enrolled quickly. What if he’d said yes and leronlimab was included in that trial or another trial (maybe funded by the NIH)? The trial would’ve likely been enrolled quickly, completed and the combo approved. AND CYDY could still run a mono trial for leronlimab. This is just one example, that we know of, where NP prevented leronlimab from realizing its full potential. Him signing these terrible deals with Fife indicate other problems.